Integrating Pulmonology and Metabolism: Adipokines in COPD from a Systematic Review and Meta-analysis Perspective
DOI:
https://doi.org/10.36283/ziun-pjmd14-3/066Keywords:
Adipokines, Leptin, Chronic Obstructive Pulmonary Disease, Disorder, PulmonaryAbstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is increasingly recognized not just as a pulmonary disorder but as a complex systemic syndrome involving chronic inflammation, metabolic dysregulation, and immune imbalance. This systematic review and meta-analysis aim to evaluate circulating adipokine profiles in COPD patients, exploring their diagnostic significance, correlation with disease severity, and potential as biomarkers or therapeutic targets.
Methods: Following PRISMA 2020 guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science. A random-effects meta-analysis assessed standardized mean differences (SMDs) for key adipokines. Risk of bias was evaluated using the Newcastle-Ottawa Scale, and evidence certainty was assessed using the GRADE framework.
Results: Twelve eligible studies comprising 2,100 COPD patients and 2,100 controls were included. Leptin (1.57 [-0.02 to 3.16] double armed; 19.59 [14.01-25.18] single armed), resistin (0.67 [-0.27 to 1.60]), and adiponectin (-0.18 [-2.13 to 1.77] double armed; 7.83 [6.95 to 8.71] single armed) levels showed statistically significant differences between COPD patients and controls (p < 0.001 for all), with high heterogeneity (>60%). Elevated leptin and resistin levels were associated with systemic inflammation and poorer clinical outcomes, whereas adiponectin was often reduced despite its anti-inflammatory properties. Sensitivity and subgroup analyses reinforced these findings. The certainty of evidence ranged from low to moderate.
Discussion: Adipokines reflect systemic inflammation and metabolic imbalance in COPD, highlighting their potential role in phenotypic stratification and disease monitoring. While promising, translation to clinical practice requires further standardized, longitudinal, and mechanistic research.
References
1. Backman H, Sawalha S, Nilsson U, Hedman L, Stridsman C, Vanfleteren LEGW, et al. Cause-Specific Death in Chronic Airway Obstruction and Restrictive Spirometric Pattern. Ann Am Thorac Soc. 2022 Oct;19(10):1783-1787. doi: 10.1513/AnnalsATS.202203-243RL.
2. He J, Li X. Relationship between chronic obstructive pulmonary disease and adiponectin concentrations: An updated meta-analysis and single-cell RNA sequencing. Medicine (Baltimore). 2023 Aug 18;102(33):e34825. doi: 10.1097/MD.0000000000034825.
3. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Martín-Rodríguez A, Martínez-Guardado I, Navarro-Jiménez E, et al. The Role of Adipokines in Health and Disease. Biomedicines. 2023 Apr 27;11(5):1290. doi: 10.3390/biomedicines11051290.
4. Tilg H, Ianiro G, Gasbarrini A, Adolph TE. Adipokines: masterminds of metabolic inflammation. Nat Rev Immunol. 2025 Apr;25(4):250-265. doi: 10.1038/s41577-024-01103-8.
5. Gao J, Deng M, Li Y, Yin Y, Zhou X, Zhang Q, et al. Resistin as a Systemic Inflammation-Related Biomarker for Sarcopenia in Patients With Chronic Obstructive Pulmonary Disease. Front Nutr. 2022 Jul 12;9:921399. doi: 10.3389/fnut.2022.921399.
6. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020.
7. Zielinski M, Chwalba A, Jastrzebski D, Ziora D. Adipokines in interstitial lung diseases. Respir Physiol Neurobiol. 2023 Sep;315:104109. doi: 10.1016/j.resp.2023.104109.
8. Perrotta F, Scialò F, Mallardo M, Signoriello G, D'Agnano V, Bianco A, et al. Adiponectin, Leptin, and Resistin Are Dysregulated in Patients Infected by SARS-CoV-2. Int J Mol Sci. 2023 Jan 6;24(2):1131. doi: 10.3390/ijms24021131.
9. Kim S, Rhee CK, Jo YS, Lim JU, Kim SH, Yoo J, et al. Longitudinal analysis of adiponectin to leptin and apolipoprotein B to A1 ratios as markers of future airflow obstruction and lung function decline. Sci Rep. 2024 Nov 27;14(1):29502. doi: 10.1038/s41598-024-80055-4.
10. Lu L, Cheng M. Serum levels of HMW adiponectin and its receptors are associated with cytokine levels and clinical characteristics in chronic obstructive pulmonary disease. Open Med (Wars). 2024 Feb 5;19(1):20240904. doi: 10.1515/med-2024-0904.
11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
12. Małujło-Balcerska E, Kumor-Kisielewska A, Śmigielski W. Leptin, resistin and fetuin a concentration as the potential useful biomarkers in stable COPD - An exploratory study. Cytokine. 2023 Sep;169(1):156275. doi: 10.1016/j.cyto.2023.156275.
13. Hryniuk O, Khukhlina O, Liakhovych O, Hutsuliak V, Hnatkovych S. Metabolic and Adipocytokine Preconditions For Progression Of Non-Alcoholic Steatohepatitis In Obesity Patients Due To Comorbidity With Chronic Obstructive Pulmonary Disease. PMP [Internet]. 2020 Nov;1(1):28-35. doi: 10.12955/pmp.v1.94.
14. Amanullah, Khan T, Saad M, Shaheen S, Rehman AU, Khan S. Circulatory and Adipose tissue Leptin and Adiponectin in relationship to resting energy expenditure in patients with Chronic Obstructive Pulmonary Disease. Pak. J. Chest Med. 2022 Jun 2;28(2):236-43. https://www.pjcm.net/index.php/pjcm/article/view/862.
15. Aslani MR, Amani M, Moghadas F, Ghobadi H. Adipolin and IL-6 Serum Levels in Chronic Obstructive Pulmonary Disease. Adv Respir Med. 2022 Sep 7;90(5):391-398. doi: 10.3390/arm90050049.
16. Cuttitta G, Ferraro M, Cibella F, Alfano P, Bucchieri S, Patti AM, et al. Relationship among Body Composition, Adipocytokines, and Irisin on Exercise Capacity and Quality of Life in COPD: A Pilot Study. Biomolecules. 2022 Dec 27;13(1):48. doi: 10.3390/biom13010048.
17. Vanfleteren LEGW, Weidner J, Franssen FME, Gaffron S, Reynaert NL, Wouters EFM, et al. Biomarker-based clustering of patients with chronic obstructive pulmonary disease. ERJ Open Res. 2023 Feb 6;9(1):00301-2022. doi: 10.1183/23120541.00301-2022.
18. Zhelyazkova YA, Tacheva TT, Dimov DM, Vlaykova DG, Bivolarska AV, Vlaykova TI. Possible Role of Serum Leptin as Biomarker in COPD. Folia Med (Plovdiv). 2019 Dec 31;61(4):512-521. doi: 10.3897/folmed.61.e47745.
19. Nigro E, Mosella M, Daniele A, Mallardo M, Accardo M, Bianco A, et al. Adiponectin Increase in Patients Affected by Chronic Obstructive Pulmonary Disease with Overlap of Bronchiectasis. Life (Basel). 2023 Feb 4;13(2):444. doi: 10.3390/life13020444.
20. Wang Z, Zhou X, Deng M, Yin Y, Li Y, Zhang Q, et al. Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study. BMC Pulm Med. 2023 Oct 18;23(1):394. doi: 10.1186/s12890-023-02702-2.
21. Wu D, Wang Z, Wang K, Wang Y, Wang T. The association between adipokines and pulmonary diseases: a mendelian randomization study. BMC Pulm Med. 2024 Jan 23;24(1):50. doi: 10.1186/s12890-024-02863-8.
22. Ghobadi H, Mokhtari S, Aslani MR. Serum levels of visfatin, sirtuin-1, and interleukin-6 in stable and acute exacerbation of chronic obstructive pulmonary disease. J Res Med Sci. 2021 Feb 27;26(1):17. doi: 10.4103/jrms.JRMS_626_19.
23. Vassiliou AG, Vitsas V, Kardara M, Keskinidou C, Michalopoulou P, Rovina N, et al. Study of inflammatory biomarkers in COPD and asthma exacerbations. Adv Respir Med. 2020;88(6):558-566. doi: 10.5603/ARM.a2020.0188.
24. Chwalba A, Machura E, Ziora K, Ziora D. The role of adipokines in the pathogenesis and course of selected respiratory diseases. Endokrynol Pol. 2019;70(6):504-510. doi: 10.5603/EP.a2019.0051.
25. Kiernan K, MacIver NJ. The Role of the Adipokine Leptin in Immune Cell Function in Health and Disease. Front Immunol. 2021 Jan 29;11:622468. doi: 10.3389/fimmu.2020.622468.
26. Kononoff A, Vuolteenaho K, Hämäläinen M, Kautiainen H, Elfving P, Savolainen E, et al. Metabolic Syndrome, Disease Activity, and Adipokines in Patients With Newly Diagnosed Inflammatory Joint Diseases. J Clin Rheumatol. 2021 Dec 1;27(8):e349-e356. doi: 10.1097/RHU.0000000000001412.
27. Palma G, Sorice GP, Genchi VA, Giordano F, Caccioppoli C, D'Oria R, et al. Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity. Int J Mol Sci. 2022 Jul 1;23(13):7349. doi: 10.3390/ijms23137349.
28. Ren Y, Zhao H, Yin C, Lan X, Wu L, Du X, et al. Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation. Front Endocrinol (Lausanne). 2022 Jul 14;13:873699. doi: 10.3389/fendo.2022.873699.
29. Giardullo L, Corrado A, Maruotti N, Cici D, Mansueto N, Cantatore FP. Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases. Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211015034. doi: 10.1177/20587384211015034.
30. Orlowski A, Ettinger J, Bottle A, Snow S, Ashton R, Quint JK. Modifiable risk factors that may be addressed in routine care to prevent progression to and extension of multimorbidity in people with COPD: a systematic literature review. BMJ Open Respir Res. 2024 Apr 22;11(1):e002272. doi: 10.1136/bmjresp-2023-002272.
31. Liu K, Wang H. Serum adipocytokines and inflammatory cytokines in pregnant women with gestational diabetes mellitus: clinical utility and development of a risk prediction model. Expert Rev Clin Immunol. 2025 Mar;21(3):369-375. doi: 10.1080/1744666X.2024.2438714.
32. Ramakrishnan S, Janssens W, Burgel PR, Contoli M, Franssen FME, Greening NJ, et al. Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. Int J Chron Obstruct Pulmon Dis. 2021 Feb 16;16:321-332. doi: 10.2147/COPD.S287705.
33. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci (Lond). 2021 Mar 26;135(6):731-752. doi: 10.1042/CS20200895.
34. Zou RH, Nouraie SM, Karoleski C, Zhang Y, Sciurba FC, Forman DE, et al. Incident low muscle mass is associated with greater lung disease and lower circulating leptin in a tobacco-exposed longitudinal cohort. Respir Res. 2023 Sep 22;24(1):224. doi: 10.1186/s12931-023-02521-3.
35. Lendeckel F, Zylla S, Markus MRP, Ewert R, Gläser S, Völzke H, et al. Association of Cardiopulmonary Exercise Capacity and Adipokines in the General Population. Int J Sports Med. 2022 Jun;43(7):616-624. doi: 10.1055/a-1699-2380.
36. Macklin M, Thompson C, Kawano-Dourado L, Bauer Ventura I, Weschenfelder C, Trostchansky A, Marcadenti A, et al. Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation. Cells. 2023 Sep 5;12(18):2206. doi: 10.3390/cells12182206.
37. Tok Ö, Kişioğlu SV, Ersöz HÖ, Kahveci B, Göktaş Z. Effects of increased physical activity and/or weight loss diet on serum myokine and adipokine levels in overweight adults with impaired glucose metabolism. J Diabetes Complications. 2021 May;35(5):107892. doi: 10.1016/j.jdiacomp.2021.107892.
38. Oh YM, Jeong BH, Woo SY, Kim SY, Kim H, Lee JH, et al. Association of plasma adipokines with chronic obstructive pulmonary disease severity and progression. Ann Am Thorac Soc. 2015 Jul;12(7):1005-12. doi: 10.1513/AnnalsATS.201501-005OC.
39. Zhang Z, Wang J, Li Y, Liu F, Chen L, He S, et al. Proteomics and metabolomics profiling reveal panels of circulating diagnostic biomarkers and molecular subtypes in stable COPD. Respir Res. 2023 Mar 11;24(1):73. doi: 10.1186/s12931-023-02349-x.
40. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022 Jun 11;399(10342):2227-2242. doi: 10.1016/S0140-6736(22)00470-6.
41. Lim JY, Templeton SP. Regulation of lung inflammation by adiponectin. Front Immunol. 2023 Sep 1;14:1244586. doi: 10.3389/fimmu.2023.1244586.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
